JP2022523155A5 - - Google Patents
Info
- Publication number
- JP2022523155A5 JP2022523155A5 JP2021546257A JP2021546257A JP2022523155A5 JP 2022523155 A5 JP2022523155 A5 JP 2022523155A5 JP 2021546257 A JP2021546257 A JP 2021546257A JP 2021546257 A JP2021546257 A JP 2021546257A JP 2022523155 A5 JP2022523155 A5 JP 2022523155A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- antibody
- inhibitor
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962802511P | 2019-02-07 | 2019-02-07 | |
| US62/802,511 | 2019-02-07 | ||
| EP19305173.7 | 2019-02-11 | ||
| EP19305173.7A EP3693023A1 (en) | 2019-02-11 | 2019-02-11 | Use of anti-ceacam5 immunoconjugates for treating lung cancer |
| EP19305504.3 | 2019-04-18 | ||
| EP19305504 | 2019-04-18 | ||
| PCT/EP2020/052932 WO2020161214A1 (en) | 2019-02-07 | 2020-02-06 | Use of anti-ceacam5 immunoconjugates for treating lung cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022523155A JP2022523155A (ja) | 2022-04-21 |
| JP2022523155A5 true JP2022523155A5 (enExample) | 2023-01-26 |
| JP7597718B2 JP7597718B2 (ja) | 2024-12-10 |
Family
ID=71947024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021546257A Active JP7597718B2 (ja) | 2019-02-07 | 2020-02-06 | 肺がんを処置するための抗ｃｅａｃａｍ５イムノコンジュゲートの使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220080053A1 (enExample) |
| EP (1) | EP3920972A1 (enExample) |
| JP (1) | JP7597718B2 (enExample) |
| KR (1) | KR20210124260A (enExample) |
| CN (1) | CN114173823A (enExample) |
| AU (1) | AU2020219405A1 (enExample) |
| BR (1) | BR112021014636A2 (enExample) |
| CA (1) | CA3129106A1 (enExample) |
| CO (1) | CO2021010032A2 (enExample) |
| IL (1) | IL285306A (enExample) |
| MX (1) | MX2021009514A (enExample) |
| SG (1) | SG11202107843WA (enExample) |
| TW (1) | TW202045539A (enExample) |
| WO (1) | WO2020161214A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3199552T3 (da) * | 2012-11-20 | 2020-03-30 | Sanofi Sa | Anti-ceacam5-antistoffer og anvendelser heraf |
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| AU2021258464A1 (en) * | 2020-04-24 | 2023-01-05 | Sanofi | Antitumor combinations containing anti-CEACAM5 antibody conjugates, trifluridine and tipiracil |
| AU2021379882A1 (en) | 2020-11-10 | 2023-06-29 | Sanofi | Ceacam5 antibody-drug conjugate formulation |
| AU2022402334A1 (en) | 2021-12-02 | 2024-07-18 | Sanofi | Ceacam5 adc–anti-pd1/pd-l1 combination therapy |
| EP4427763A1 (en) | 2023-03-06 | 2024-09-11 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies |
| EP4719483A1 (en) | 2023-06-05 | 2026-04-08 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-pd1/pd-l1 antibodies and anti-ctla4 antibodies |
| WO2025169012A1 (en) | 2024-02-06 | 2025-08-14 | Sanofi | Methods of treating ceacam5-expressing cancers |
| WO2025184208A1 (en) * | 2024-02-27 | 2025-09-04 | Bristol-Myers Squibb Company | Anti-ceacam5 antibodies and uses thereof |
| US12521446B2 (en) | 2024-02-27 | 2026-01-13 | Bristol-Myers Squibb Company | Anti-CEACAM5 antibody drug conjugates |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5215534A (en) | 1991-12-02 | 1993-06-01 | Lawrence De Harde | Safety syringe system |
| EP0563475B1 (en) | 1992-03-25 | 2000-05-31 | Immunogen Inc | Cell binding agent conjugates of derivatives of CC-1065 |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| GB0308731D0 (en) | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
| JP5399712B2 (ja) | 2005-12-21 | 2014-01-29 | アムゲン リサーチ （ミュンヘン） ゲーエムベーハー | 可溶性ｃｅａに対する抵抗性を有する医薬組成物 |
| MX2009000709A (es) | 2006-07-18 | 2009-02-04 | Sanofi Aventis | Anticuerpo antagonista contra epha2 para el tratamiento de cancer. |
| CA2761120A1 (en) * | 2009-05-06 | 2010-11-11 | Biotest Ag | Uses of immunoconjugates targeting cd138 |
| US9427531B2 (en) | 2010-06-28 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Auto-injector |
| US9248242B2 (en) | 2012-04-20 | 2016-02-02 | Safety Syringes, Inc. | Anti-needle stick safety device for injection device |
| DK3199552T3 (da) | 2012-11-20 | 2020-03-30 | Sanofi Sa | Anti-ceacam5-antistoffer og anvendelser heraf |
| US20140155827A1 (en) | 2012-12-03 | 2014-06-05 | Mylan, Inc. | Medicament information system and method |
| US10669338B2 (en) * | 2016-06-17 | 2020-06-02 | Immunomedics, Inc. | Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1 |
| EP3634401A1 (en) * | 2017-06-07 | 2020-04-15 | Silverback Therapeutics, Inc. | Antibody construct conjugates |
| AU2022402334A1 (en) * | 2021-12-02 | 2024-07-18 | Sanofi | Ceacam5 adc–anti-pd1/pd-l1 combination therapy |
| JP2026508856A (ja) * | 2023-03-01 | 2026-03-13 | サノフイ | Ｃｅａｃａｍ５を発現する神経内分泌がんを処置するための抗ｃｅａｃａｍ５免疫複合体の使用 |
-
2020
- 2020-02-06 WO PCT/EP2020/052932 patent/WO2020161214A1/en not_active Ceased
- 2020-02-06 BR BR112021014636A patent/BR112021014636A2/pt unknown
- 2020-02-06 JP JP2021546257A patent/JP7597718B2/ja active Active
- 2020-02-06 MX MX2021009514A patent/MX2021009514A/es unknown
- 2020-02-06 US US17/425,603 patent/US20220080053A1/en active Pending
- 2020-02-06 AU AU2020219405A patent/AU2020219405A1/en active Pending
- 2020-02-06 CA CA3129106A patent/CA3129106A1/en active Pending
- 2020-02-06 KR KR1020217025390A patent/KR20210124260A/ko not_active Ceased
- 2020-02-06 SG SG11202107843WA patent/SG11202107843WA/en unknown
- 2020-02-06 CN CN202080012901.6A patent/CN114173823A/zh active Pending
- 2020-02-06 EP EP20702487.8A patent/EP3920972A1/en active Pending
- 2020-02-07 TW TW109103884A patent/TW202045539A/zh unknown
-
2021
- 2021-07-29 CO CONC2021/0010032A patent/CO2021010032A2/es unknown
- 2021-08-02 IL IL285306A patent/IL285306A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022523155A5 (enExample) | ||
| US12497465B2 (en) | Combination of antibody-drug conjugate and tubulin inhibitor | |
| TWI847992B (zh) | 抗體-藥物結合物之有效的製造方法 | |
| CN111587124B (zh) | Ror1抗体免疫缀合物 | |
| JP7512202B2 (ja) | ヒト化抗前立腺特異的膜抗原（ｐｓｍａ）抗体薬物複合体 | |
| US20230110128A1 (en) | Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor | |
| JP2020525542A5 (enExample) | ||
| JP2022191301A5 (enExample) | ||
| JP2023022328A5 (enExample) | ||
| JP2025026600A (ja) | 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｅｇｆｒ－ｔｋｉ抵抗性の非小細胞肺癌の治療方法 | |
| JP2020172541A (ja) | 抗体薬物複合体組成物の製剤化方法 | |
| JP2016512832A5 (enExample) | ||
| JP2024545428A5 (enExample) | ||
| JP2023540611A5 (enExample) | ||
| JP2024545427A5 (enExample) | ||
| US20250339551A1 (en) | An antibody-drug conjugate having two or more different functional small molecules for enhanced treatment of refractory diseases | |
| JP2023525965A (ja) | αエノラーゼ抗体を含む薬物複合体及びこれらの使用 | |
| TW201905000A (zh) | 含有抗globo h抗體之抗體－藥物共軛物及其用途 | |
| JP2022532402A5 (enExample) | ||
| US20250121088A1 (en) | Anti-muc1* antibody drug complexes and uses thereof | |
| JP2016511257A (ja) | 癌の治療における抗ｇｃｃ抗体−薬物複合体及びｄｎａ損傷剤の投与 | |
| RU2021125713A (ru) | Применение иммуноконъюгатов к ceacam5 для лечения рака легкого | |
| RU2025126657A (ru) | Применение иммуноконъюгатов, связывающих ceacam5, для лечения видов нейроэндокринного рака, экспрессирующих ceacam5 | |
| KR20250163875A (ko) | 핵 위치화 폴리펩타이드 및 컨주게이트 및 이의 용도 | |
| CN121941709A (zh) | 抗cdh17抗体-药物偶联物及其制备和使用方法 |